247 related articles for article (PubMed ID: 11484959)
21. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT.
Papajik T; Myslivecek M; Skopalova M; Malan A; Buriankova E; Koza V; Hnatkova M; Trneny M; Sedova Z; Kubova Z; Koranda P; Flodr P; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2011; 58(4):291-7. PubMed ID: 21524147
[TBL] [Abstract][Full Text] [Related]
22. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
23. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
[TBL] [Abstract][Full Text] [Related]
24. Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI.
De Paepe KN; De Keyzer F; Wolter P; Bechter O; Dierickx D; Janssens A; Verhoef G; Oyen R; Vandecaveye V
J Magn Reson Imaging; 2018 Oct; 48(4):897-906. PubMed ID: 29656584
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
26. Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma.
Xiao-Xue W; Xinyue H; Lijun Z
Med Clin (Barc); 2020 Jan; 154(2):61-65. PubMed ID: 31757394
[TBL] [Abstract][Full Text] [Related]
27. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
[TBL] [Abstract][Full Text] [Related]
29. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
31. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.
Hoffmann M; Kletter K; Diemling M; Becherer A; Pfeffel F; Petkov V; Chott A; Raderer M
Ann Oncol; 1999 Oct; 10(10):1185-9. PubMed ID: 10586335
[TBL] [Abstract][Full Text] [Related]
33. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
Kaddu-Mulindwa D; Altmann B; Held G; Angel S; Stilgenbauer S; Thurner L; Bewarder M; Schwier M; Pfreundschuh M; Löffler M; Menhart K; Grosse J; Ziepert M; Herrmann K; Dührsen U; Hüttmann A; Barbato F; Poeschel V; Hellwig D
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3550-3559. PubMed ID: 33928400
[TBL] [Abstract][Full Text] [Related]
34. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
35. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
36. Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT.
Ribeiro TH; S R; Castro AC; Paulino E; Mamede M
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):109-111. PubMed ID: 28355370
[TBL] [Abstract][Full Text] [Related]
37. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
38. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
39. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]